Therapy Areas: Autoimmune
Rigel announces European launch of TAVLESSE for treatment of chronic immune thrombocytopenia
10 July 2020 -

Biotechnology company Rigel Pharmaceuticals Inc (Nasdaq:RIGL) said on Thursday that its European collaborative partner Grifols SA has launched TAVLESSE (fostamatinib disodium hexahydrate) in Germany and the UK.

TAVLESSE was approved by the European Commission in January 2020 for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments.

Marketed in the United States under the brand name TAVALISSE, the drug is an oral spleen tyrosine kinase (SYK) inhibitor that targets the underlying autoimmune cause of ITP by impeding platelet destruction.

In patients with ITP the immune system attacks and destroys the body's own blood platelets, which play an active role in blood clotting and healing. Common symptoms of ITP are excessive bruising and bleeding.

Login
Username:

Password: